EP2262771A1 - A method for the preparation of dabigatran - Google Patents
A method for the preparation of dabigatranInfo
- Publication number
- EP2262771A1 EP2262771A1 EP09719117A EP09719117A EP2262771A1 EP 2262771 A1 EP2262771 A1 EP 2262771A1 EP 09719117 A EP09719117 A EP 09719117A EP 09719117 A EP09719117 A EP 09719117A EP 2262771 A1 EP2262771 A1 EP 2262771A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- reaction
- formula
- compound
- dabigatran
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Definitions
- Dabigatran is an anticoagulant compound and it is used for treatment of thromboses, cardiovascular diseases, and the like.
- the invention deals with a new method for the manufacture of 3-([2-[[(4-(N-n- hexyloxycarbonylcarbamimidoyl)phenylamino] -methyl] ] - 1 -methyl- 1 H-benzimidazole-5 - carbonyl]-pyridin-2-yl-amino)ethyl propionate of formula VIII
- Hydrogen chloride is dissolved in an organic solvent selected, e.g., from the group of ethers, esters, ketones and alcohols. Diethylether appears to be the most suitable one.
- the next production stage is reduction of the nitro group to the amino group.
- the procedure according to the present invention is performed in a solvent mixture of ethanol and water.
- the reagent is sodium dithionite. It is not necessary to operate at elevated pressure or very high temperature. This procedure is much less costly and more advantageous from the economic point of view.
- Substance III enters the reaction in the hydrochloride form, which has a positive influence on the course of the reaction and purity of the product. Using the combination of changing the quality and composition of the starting substance and of the method of reduction of the nitro group it is possible to obtain product IV with a minimum content of impurities, i.e. less that 5%, preferably less than 1%.
- compound VI is obtained in the form of a salt with oxalic acid.
- This salt is simply re-purified by further crystallization, which provides the advanced intermediate VI in a yield that is acceptable for industrial production, approximately 80 to 90%.
- This crystallization can be carried out from a polar protic organic solvent, preferably from lower Ci - C 5 alcohols, e.g. from ethyl alcohol.
- the crude hydrochloride was crystallized from a mixture of denatured non-dried ethanol with acetonitrile 9:1.
- Substance III was put into 1500 ml of the ethanol - water mixture 1 :1 and heated up to 50 °C. This way a solution was created to which solid sodium dithionite was added quickly and under intensive stirring. After the starting substance has reacted the reaction mixture was concentrated in a vacuum evaporator. After separation of oil the concentration was completed and the product was extracted with ethyl acetate. After its drying with sodium sulphate the solvent is evaporated. The product is obtained as a brown, very viscous liquid. Yield: 82 g (81.3%); HPLC: 95%
- Substance V and l,l'-carbonyldiimidazole are put into a flask blown with an inert gas. 2000 ml of dry THF are added and the mixture is boiled under a reflux condenser with a calcium- chloride tube for 40 minutes. After 40 minutes a solution of substance IV in 330 ml of dry THF is added to the mixture and the mixture is boiled for another 5 hours. After expiration of this time period the reaction mixture is slightly cooled and THF is removed by distillation in vacuum. 1000 ml of glacial acetic acid are added to the honey-like brown residue and the resulting solution is boiled for 1 hour. The acid is distilled off and the produced residue is dissolved in dichloromethane (850 ml) and shaken with water. The separated organic layer is dried with sodium sulphate and the solvent is evaporated. A dark brown honey-like residue is obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2008-165A CZ305085B6 (cs) | 2008-03-14 | 2008-03-14 | Způsob přípravy dabigatranu |
PCT/CZ2009/000037 WO2009111997A1 (en) | 2008-03-14 | 2009-03-10 | A method for the preparation of dabigatran |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2262771A1 true EP2262771A1 (en) | 2010-12-22 |
Family
ID=40627441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09719117A Withdrawn EP2262771A1 (en) | 2008-03-14 | 2009-03-10 | A method for the preparation of dabigatran |
Country Status (6)
Country | Link |
---|---|
US (1) | US8394961B2 (ru) |
EP (1) | EP2262771A1 (ru) |
CZ (1) | CZ305085B6 (ru) |
EA (1) | EA018053B1 (ru) |
UA (1) | UA102248C2 (ru) |
WO (1) | WO2009111997A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014012880A1 (en) | 2012-07-16 | 2014-01-23 | Interquim, S.A. | Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2008669A3 (cs) * | 2008-10-24 | 2010-05-05 | Zentiva, A. S. | Zpusob prípravy dabigatranu a jeho meziprodukty |
MX2013000295A (es) | 2010-07-09 | 2013-05-28 | Esteve Quimica Sa | Procedimiento de preparacion de un inhibidor especifico de la trombina. |
JP2013531004A (ja) * | 2010-07-09 | 2013-08-01 | エステヴェ キミカ, エス.エー. | トロンビン特異的インヒビターの調製のための中間体及び方法 |
EP2649060B1 (en) * | 2010-12-06 | 2017-04-05 | MSN Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
HUP1100244A2 (hu) * | 2011-05-11 | 2012-11-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Gyógyszeripari intermedierek és eljárás elõállításukra |
WO2013024384A1 (en) * | 2011-08-12 | 2013-02-21 | Alembic Pharmaceuticals Limited | Improved process for preparation of dabigatran etexilate and its novel intermediate |
US9273030B2 (en) | 2012-04-02 | 2016-03-01 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
CN102911160B (zh) * | 2012-06-29 | 2014-10-22 | 上海奥博生物医药技术有限公司 | 一种制备和纯化达比加群酯中间体的方法 |
MX350575B (es) | 2012-09-27 | 2017-09-11 | Bayer Cropscience Ag | Procedimiento para la preparación de fenil y piridil pirrolidinas opcionalmente sustituidas. |
US9533971B2 (en) | 2012-10-29 | 2017-01-03 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the synthesis of dabigatran and its intermediates |
US10077251B2 (en) | 2012-10-29 | 2018-09-18 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the synthesis of Dabigatran Etexilate and its intermediates |
WO2015124764A1 (en) * | 2014-02-24 | 2015-08-27 | Erregierre S.P.A. | Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate |
WO2015128875A2 (en) * | 2014-02-26 | 2015-09-03 | Megafine Pharma (P) Ltd. | A process for preparation of dabigatran etexilate mesylate and intermediates thereof |
WO2015132794A1 (en) * | 2014-03-06 | 2015-09-11 | Symed Labs Limited | Improved processes for the preparation of dabigatran etexilate using novel intermediates |
CN103992241B (zh) * | 2014-06-05 | 2016-08-24 | 雅本化学股份有限公司 | N-取代苯基甘氨酸的制备方法 |
EP3165521B1 (en) | 2014-07-03 | 2019-01-16 | Shanghai Institute Of Pharmaceutical Industry | Method of preparing dabigatran etexilate intermediate and intermediate compound |
CN105461688B (zh) * | 2014-08-26 | 2017-12-29 | 上海医药工业研究院 | 苯并咪唑化合物k的合成方法 |
CN108727334B (zh) * | 2018-07-12 | 2020-10-30 | 江西国药有限责任公司 | 一种甲磺酸达比加群酯的生产工艺 |
CN109942434A (zh) * | 2019-03-26 | 2019-06-28 | 山东世纪阳光科技有限公司 | 一种大红色基g的生产方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
EP1609784A1 (de) * | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen |
DE102005061623A1 (de) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen |
EP1956018A1 (de) * | 2007-02-06 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Herstellung eines Benzimidazolderivats |
-
2008
- 2008-03-14 CZ CZ2008-165A patent/CZ305085B6/cs not_active IP Right Cessation
-
2009
- 2009-03-10 WO PCT/CZ2009/000037 patent/WO2009111997A1/en active Application Filing
- 2009-03-10 EP EP09719117A patent/EP2262771A1/en not_active Withdrawn
- 2009-03-10 UA UAA201012170A patent/UA102248C2/ru unknown
- 2009-03-10 US US12/922,214 patent/US8394961B2/en active Active
- 2009-03-10 EA EA201001394A patent/EA018053B1/ru not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO2009111997A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014012880A1 (en) | 2012-07-16 | 2014-01-23 | Interquim, S.A. | Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates |
Also Published As
Publication number | Publication date |
---|---|
EA018053B1 (ru) | 2013-05-30 |
CZ305085B6 (cs) | 2015-04-29 |
EA201001394A1 (ru) | 2011-02-28 |
US8394961B2 (en) | 2013-03-12 |
WO2009111997A1 (en) | 2009-09-17 |
CZ2008165A3 (cs) | 2009-09-23 |
UA102248C2 (ru) | 2013-06-25 |
US20110082299A1 (en) | 2011-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8394961B2 (en) | Method for the preparation of dabigatran | |
CN102356063A (zh) | 制备6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其合成中间体 | |
EP2346850A1 (en) | A method for the preparation of dabigatran and its intermediates | |
CN105198821B (zh) | 洛昔替尼的制备方法 | |
CN102746288B (zh) | 一种抗凝血药及其关键中间体的制备方法 | |
CN106632033A (zh) | 乐伐替尼的一种制备方法 | |
CN104829590B (zh) | 一种纯化曲格列汀的方法 | |
EA036663B1 (ru) | Способ получения азоксистробина | |
JP6174161B2 (ja) | 2−アミノニコチン酸ベンジルエステル誘導体の製造方法 | |
RU2470919C2 (ru) | Способ получения соединения толуидина | |
US20190300484A1 (en) | An improved process for the preparation of regorafenib | |
WO2011010579A1 (ja) | 光学活性ニペコタミドの製造方法 | |
KR100574350B1 (ko) | 2-아미노피리딘 유도체의 제조방법 | |
KR20200014305A (ko) | 3-아릴 프로피온 아미드 화합물 및 3-아릴 프로피온산 에스테르 화합물의 제조 방법 | |
CN103012264B (zh) | 3‑取代氨基‑六氢‑1h‑氮杂环庚烷的拆分方法 | |
WO2016116074A1 (en) | A method of producing highly pure rilpivirine and its salts | |
CN107011254B (zh) | 一种2-氨基-4-甲基吡啶的合成及其纯化方法 | |
RU2409554C1 (ru) | Способ получения 4-(3,4-диаминофенокси)бензойной кислоты | |
CN112939893A (zh) | 一种4-(4-氨基苯基)-3-吗啉酮的合成方法 | |
CN103804287B (zh) | 一种2-氯异烟酸的制备方法 | |
RU2481328C1 (ru) | Способ получения нитраминопропионитрила | |
KR102719583B1 (ko) | 테리플루노미드의 신규한 제조 공정 | |
RU2722316C2 (ru) | Новый способ получения терифлуномида | |
CN114560862A (zh) | 一种吡咯并[1,2-a]喹喔啉-4(5h)-酮及其衍生物的合成方法 | |
WO2021241725A1 (ja) | 高純度のn-(5-メトキシ―2-フェノキシフェニル)メタンスルホンアミド及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100916 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20151001 |